Boceceprevir

[Anonymous]

this is exactly right. most docs would actually prefer anemia management over severe rash because they keep patients on/complete treatment. rash patients will have to stop treatment and start all over again.

Keep talking about the rash Merck and continue to show the "pictures" that we are collecting from physicians. The FDA gave much more praise to Vertex for doing the right things and having things in place. For you? The FDA (not Vertex) was startled that you did not bring forth DDI information, was disappointed in the use of a non-approved drug (Epo), and was amazed that Merck wanted an indication for null responders "based on your assumptions" vs acutally studying the drug. Once physicians see the real numbers of cases of rash and see how to handle it, your credibility will continue to be shot. You should hope you get 30% of share.